Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison

• Main Authors: Bo Zheng (Author), Shinya Goto (Author), Regina Clementi (Author), John Feaster (Author), Danielle Duffy (Author), Penelope Dalitz (Author), Jolanta Airey (Author), Serge Korjian (Author), Michael A. Tortorici (Author), John Roberts (Author), C. Michael Gibson (Author)
• Format: Book
• Published: Wiley, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract CSL112 (apolipoprotein A‐I [apoA‐I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed to compare the pharmacokinetics (PKs), pharmacodyn...